Precision-Designed Parasiticides
Redefining drug discovery design in animal health with science built on precision, compassion and innovation.
Targeting the Molecular Infrastructure of Parasites
ASTRA Therapeutics is a technology pioneer, redefining parasiticides through the specificity of Parabulins®, a new class of drugs.
At ASTRA Therapeutics, we see microtubules as both the foundation of life and a key weakness in parasites. These dynamic structures enable parasite invasion, replication, and survival – making them an ideal drug target. By disrupting parasite microtubules with precision, we are pioneering new strategies to overcome parasitic diseases.
Our Challenge
Parasites are harder to treat than bacteria or viruses because they share many molecular features with their hosts, making it difficult to target them without causing harm. This challenge, combined with rising drug resistance, is a growing threat to global health and food security. With our revolutionary ParaX® platform, we are changing this – designing highly selective treatments that attack parasite microtubules while protecting host cells.
Revolutionising the Fight
At ASTRA Therapeutics, we are advancing precision drug design to combat parasites. Our proprietary technology has led to the discovery of multiple Parabulins® – next-generation inhibitors that target parasite microtubules while leaving host cells unharmed. Designed to fight a wide range of protozoan and worm parasites, Parabulins® offer treatments that are not only highly effective but also safer for animals, setting a new standard in parasite control.
Explore how Parabulins® are changing the game in parasitic disease treatment.
Join us in shaping a healthier future at ASTRA Therapeutics.
CONTACT US